Answers are grounded in this paper and cite their sources.
Retrospective cohort study evaluates outcomes of adding nimotuzumab in patients with pancreatic cancer, suggesting potential benefits for those with high EGFR expression.
e16375 Background: This study aimed to evaluate whether adding nimotuzumab to an albumin-bound paclitaxel plus gemcitabine (AG) regimen could improve outcomes in these patients. Methods: We analyzed data from 100 patients with BRPC/LAPC. Patients were divided into a control group (AG alone, n=57) and a study group (AG+nimotuzumab, n=43). The primary endpoint was overall survival (OS). Results: The disease control rate was 100% in both groups. The objective response rate was higher in the study group (12% vs. 4%, P=0.238), accompanied by a significantly greater mean reduction in tumor diameter (-13.7% vs. -8.2%, P=0.019). The R0 resection rate was comparable (81.4% vs. 87.7%, P=0.552). As of May 5, 2025, the median OS (mOS) was not significantly different between groups (25 vs. 24 months, P=0.229). However, in the high EGFR expression subgroup (n=50), the study group showed significantly longer mOS (33 vs. 23 months, P=0.016). Similarly, in this subgroup, the study group had favorable trends in median PFS (23 vs. 16 months, P=0.051) and significantly longer median disease-free survival (25 vs. 16 months, P=0.0025). The median PFS in the overall population was 18 vs. 17 months (P=0.279). The safety profile was comparable, with grade 3 adverse events occurring in 7.0% (control) and 4.7% (study) of patients. Conclusions: The addition of nimotuzumab to neoadjuvant AG chemotherapy demonstrated promising efficacy, particularly in patients with high EGFR expression, and was well-tolerated. These results support further investigation in prospective randomized trials.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: